Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,180,668

« Back to Dashboard

Summary for Patent: 5,180,668

Title: Hirudin derivative
Abstract:A hirudin derivative which has the N-terminal amino acid sequence Leu-Thr-Tyr-Thr-Asp shows high biological activity. Moreover, this hirudin derivative can be obtained very efficiently by genetic engineering preparation in yeasts.
Inventor(s): Crause; Peter (Offenbach, DE), Habermann; Paul (Frankfurt am Main, DE), Tripier; Dominique (Eppstein/Taunus, DE)
Assignee: Hoechst Aktiengesellschaft (Frankfurt am Main, DE)
Application Number:07/295,422
Patent Claim Types:
see list of patent claims
Compound; Process;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,180,668

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany3805540Feb 23, 1988

International Patent Family for Patent: 5,180,668

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany19775033► Subscribe
European Patent Office0324712► SubscribeSPC/GB97/077United Kingdom► Subscribe
European Patent Office0324712► Subscribe97C0046Belgium► Subscribe
European Patent Office0324712► SubscribeC970027Netherlands► Subscribe
European Patent Office0324712► Subscribe56/1997Austria► Subscribe
European Patent Office0316650► Subscribe
Denmark173366► Subscribe
Denmark630688► Subscribe
Denmark13189► Subscribe
Denmark172350► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus